Answers are grounded in this paper and cite their sources.
Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.
No takes yet. Share an insight, caveat, or question.
Quijada‐Álamo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: